NCT05653817View on ClinicalTrials.gov

Advanced or Metastatic Cholangiocarcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Cholangiocarcinoma
Interventions
DRUG

Carrilizumab

Carrilizumab 200mg Q3W d1

DRUG

Albumin-bound paclitaxel

Albumin-bound paclitaxel 125 mg/m2 d1,8

DRUG

Apatinib

Apatinib mesylate tablets for treatment: 250mg

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT05653817 - Advanced or Metastatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter